Exclusive and Combined Use of Statins and Aspirin and the Risk of Pancreatic Cancer: A Case-Control Study

Livia Archibugi, Matteo Piciucchi, Serena Stigliano, Roberto Valente, Giulia Zerboni, Viola Barucca, Michele Milella, Patrick Maisonneuve, Gianfranco Delle Fave, Gabriele Capurso

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Data on the association between aspirin and statin use and Pancreatic Ductal AdenoCarcinoma (PDAC) risk are conflicting. These drugs are often co-prescribed, but no studies evaluated the potential combined or confounding effect of the two at the same time. We aimed to investigate the association between aspirin and statin exclusive and combined use and PDAC occurrence. Data on environmental factors, family and medical history were screened in a case-control study. PDAC cases were matched to controls for age and gender. Power calculation performed ahead. Odds ratios (OR) and 95% confidence intervals(CI) were obtained from multivariable logistic regression analysis. In 408 PDAC patients and 816 matched controls, overall statin (OR 0.61; 95%CI,0.43-0.88), but not aspirin use was associated to reduced PDAC risk. Compared to non-users, exclusive statin (OR 0.51; 95%CI,0.32-0.80) and exclusive aspirin users (OR 0.64; 95%CI,0.40-1.01) had reduced PDAC risk. Concomitant statin and aspirin use did not further reduce the risk compared with statin use alone and no interaction was evident. Statin protective association was dose-dependent, and consistent in most subgroups, being stronger in smokers, elderly, obese and non-diabetic patients. The present study suggests that statin use is associated to reduced PDAC risk, supporting a chemopreventive action of statins on PDAC.

Original languageEnglish
Article number13024
JournalScientific Reports
Volume7
Issue number1
DOIs
Publication statusPublished - Dec 1 2017

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Pancreatic Neoplasms
Aspirin
Case-Control Studies
Adenocarcinoma
Odds Ratio
Confidence Intervals
Medical History Taking
Logistic Models
Regression Analysis

ASJC Scopus subject areas

  • General

Cite this

Archibugi, L., Piciucchi, M., Stigliano, S., Valente, R., Zerboni, G., Barucca, V., ... Capurso, G. (2017). Exclusive and Combined Use of Statins and Aspirin and the Risk of Pancreatic Cancer: A Case-Control Study. Scientific Reports, 7(1), [13024]. https://doi.org/10.1038/s41598-017-13430-z

Exclusive and Combined Use of Statins and Aspirin and the Risk of Pancreatic Cancer : A Case-Control Study. / Archibugi, Livia; Piciucchi, Matteo; Stigliano, Serena; Valente, Roberto; Zerboni, Giulia; Barucca, Viola; Milella, Michele; Maisonneuve, Patrick; Delle Fave, Gianfranco; Capurso, Gabriele.

In: Scientific Reports, Vol. 7, No. 1, 13024, 01.12.2017.

Research output: Contribution to journalArticle

Archibugi, L, Piciucchi, M, Stigliano, S, Valente, R, Zerboni, G, Barucca, V, Milella, M, Maisonneuve, P, Delle Fave, G & Capurso, G 2017, 'Exclusive and Combined Use of Statins and Aspirin and the Risk of Pancreatic Cancer: A Case-Control Study', Scientific Reports, vol. 7, no. 1, 13024. https://doi.org/10.1038/s41598-017-13430-z
Archibugi, Livia ; Piciucchi, Matteo ; Stigliano, Serena ; Valente, Roberto ; Zerboni, Giulia ; Barucca, Viola ; Milella, Michele ; Maisonneuve, Patrick ; Delle Fave, Gianfranco ; Capurso, Gabriele. / Exclusive and Combined Use of Statins and Aspirin and the Risk of Pancreatic Cancer : A Case-Control Study. In: Scientific Reports. 2017 ; Vol. 7, No. 1.
@article{4324cf9ac5aa4b5295fb43acfe3d9a5a,
title = "Exclusive and Combined Use of Statins and Aspirin and the Risk of Pancreatic Cancer: A Case-Control Study",
abstract = "Data on the association between aspirin and statin use and Pancreatic Ductal AdenoCarcinoma (PDAC) risk are conflicting. These drugs are often co-prescribed, but no studies evaluated the potential combined or confounding effect of the two at the same time. We aimed to investigate the association between aspirin and statin exclusive and combined use and PDAC occurrence. Data on environmental factors, family and medical history were screened in a case-control study. PDAC cases were matched to controls for age and gender. Power calculation performed ahead. Odds ratios (OR) and 95{\%} confidence intervals(CI) were obtained from multivariable logistic regression analysis. In 408 PDAC patients and 816 matched controls, overall statin (OR 0.61; 95{\%}CI,0.43-0.88), but not aspirin use was associated to reduced PDAC risk. Compared to non-users, exclusive statin (OR 0.51; 95{\%}CI,0.32-0.80) and exclusive aspirin users (OR 0.64; 95{\%}CI,0.40-1.01) had reduced PDAC risk. Concomitant statin and aspirin use did not further reduce the risk compared with statin use alone and no interaction was evident. Statin protective association was dose-dependent, and consistent in most subgroups, being stronger in smokers, elderly, obese and non-diabetic patients. The present study suggests that statin use is associated to reduced PDAC risk, supporting a chemopreventive action of statins on PDAC.",
author = "Livia Archibugi and Matteo Piciucchi and Serena Stigliano and Roberto Valente and Giulia Zerboni and Viola Barucca and Michele Milella and Patrick Maisonneuve and {Delle Fave}, Gianfranco and Gabriele Capurso",
year = "2017",
month = "12",
day = "1",
doi = "10.1038/s41598-017-13430-z",
language = "English",
volume = "7",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Exclusive and Combined Use of Statins and Aspirin and the Risk of Pancreatic Cancer

T2 - A Case-Control Study

AU - Archibugi, Livia

AU - Piciucchi, Matteo

AU - Stigliano, Serena

AU - Valente, Roberto

AU - Zerboni, Giulia

AU - Barucca, Viola

AU - Milella, Michele

AU - Maisonneuve, Patrick

AU - Delle Fave, Gianfranco

AU - Capurso, Gabriele

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Data on the association between aspirin and statin use and Pancreatic Ductal AdenoCarcinoma (PDAC) risk are conflicting. These drugs are often co-prescribed, but no studies evaluated the potential combined or confounding effect of the two at the same time. We aimed to investigate the association between aspirin and statin exclusive and combined use and PDAC occurrence. Data on environmental factors, family and medical history were screened in a case-control study. PDAC cases were matched to controls for age and gender. Power calculation performed ahead. Odds ratios (OR) and 95% confidence intervals(CI) were obtained from multivariable logistic regression analysis. In 408 PDAC patients and 816 matched controls, overall statin (OR 0.61; 95%CI,0.43-0.88), but not aspirin use was associated to reduced PDAC risk. Compared to non-users, exclusive statin (OR 0.51; 95%CI,0.32-0.80) and exclusive aspirin users (OR 0.64; 95%CI,0.40-1.01) had reduced PDAC risk. Concomitant statin and aspirin use did not further reduce the risk compared with statin use alone and no interaction was evident. Statin protective association was dose-dependent, and consistent in most subgroups, being stronger in smokers, elderly, obese and non-diabetic patients. The present study suggests that statin use is associated to reduced PDAC risk, supporting a chemopreventive action of statins on PDAC.

AB - Data on the association between aspirin and statin use and Pancreatic Ductal AdenoCarcinoma (PDAC) risk are conflicting. These drugs are often co-prescribed, but no studies evaluated the potential combined or confounding effect of the two at the same time. We aimed to investigate the association between aspirin and statin exclusive and combined use and PDAC occurrence. Data on environmental factors, family and medical history were screened in a case-control study. PDAC cases were matched to controls for age and gender. Power calculation performed ahead. Odds ratios (OR) and 95% confidence intervals(CI) were obtained from multivariable logistic regression analysis. In 408 PDAC patients and 816 matched controls, overall statin (OR 0.61; 95%CI,0.43-0.88), but not aspirin use was associated to reduced PDAC risk. Compared to non-users, exclusive statin (OR 0.51; 95%CI,0.32-0.80) and exclusive aspirin users (OR 0.64; 95%CI,0.40-1.01) had reduced PDAC risk. Concomitant statin and aspirin use did not further reduce the risk compared with statin use alone and no interaction was evident. Statin protective association was dose-dependent, and consistent in most subgroups, being stronger in smokers, elderly, obese and non-diabetic patients. The present study suggests that statin use is associated to reduced PDAC risk, supporting a chemopreventive action of statins on PDAC.

UR - http://www.scopus.com/inward/record.url?scp=85031298365&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031298365&partnerID=8YFLogxK

U2 - 10.1038/s41598-017-13430-z

DO - 10.1038/s41598-017-13430-z

M3 - Article

AN - SCOPUS:85031298365

VL - 7

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 13024

ER -